Accueil Ernstrade Bourse Actualite Stock


Place: Copenhagen Stock Exchange

BioPorto A/S is a Denmark-based biotechnology company. It develops and markets antibodies and antibody-based products, including tests to diagnose human disease, for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage. BioPorto’s strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases. The Company wholly owns the subsidiary BioPorto Diagnositcs A/S which is engaged in the production, distribution and e-commerce of monoclonal antibody-producing cell lines.


Copyright   2013